Several possible studies
Story checked
PAPILLON trial: Amivantamab plus chemotherapy adds months of survival in rare lung cancer (opens in a new tab)
medicalxpress.com · 2026-09-15
Short answer
Several possible studiesNo clear answer.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
PAPILLON trial: Amivantamab plus chemotherapy adds months of survival in rare lung cancer
medicalxpress.com · 2026-09-15
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 6Not checkedFinal results from the PAPILLON trial confirm that amivantamab added to chemotherapy provides durable clinical benefit and the longest median overall survival reported to date for people with this rare form of lung cancer.View evidenceHide evidence
As statedlongest median overall survival reported to date
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 6Not checkedThe phase III trial previously showed a major progression-free survival benefit in non-small cell lung cancer with an EGFR exon 20 insertion mutation, leading to FDA approval of amivantamab in March 2024.View evidenceHide evidence
As statedmajor progression-free survival benefit
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 6Not checkedThe final overall survival analysis reportedly reached 34.3 months with amivantamab plus chemotherapy versus 27.9 months with chemotherapy alone, a clinically meaningful 6-month difference.View evidenceHide evidence
As stated34.3 vs. 27.9 months; 6 months
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 6Not checkedThe article says progression-free survival was 11.4 months with amivantamab plus chemotherapy versus 6.7 months with chemotherapy alone, cutting disease progression risk by 60%.View evidenceHide evidence
As stated11.4 vs. 6.7 months; 60%
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 6Not checkedThe article says objective response rates were 73% in the amivantamab arm versus 40% in the control chemotherapy arm, and patient-reported quality-of-life outcomes favored the amivantamab arm.View evidenceHide evidence
As stated73% vs. 40%
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 6Not checkedThe article says the overall survival analysis did not reach statistical significance, and that interpretation was limited by reduced power and substantial crossover, with about three-quarters of patients initially assigned to chemotherapy later receiving amivantamab after progression.View evidenceHide evidence
As statedabout three-quarters
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Crossref, Europe PMC · 15 candidate papers
Case Report: Targeting EGFR exon 20 insertion and MTAP loss in refractory metastatic upper tract urothelial carcinoma.
Frontiers in Oncology · 2026 · PubMed
Faculty Opinions recommendation of Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · 2023 · Crossref
Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available - Practical Dose Selection Considerations and Real-World Access Challenges.
2026 · Europe PMC
Baseline Uncommon EGFR Mutations in Non-Small-Cell Lung Cancer: Structure-Function Classification and Clinical Evidence Interpretation.
Cancer Control : Journal of the Moffitt Cancer Center · 2026 · PubMed
Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
BMC Pulmonary Medicine · 2025 · Crossref
And 10 more candidates considered.